Imagine being told your cancer will inevitably return, with no clear timeline and no further treatment options. This is the devastating reality for Mark Norris, a 52-year-old Melbourne resident battling glioblastoma, one of the deadliest forms of brain cancer. But here’s where it gets controversial: scientists at the University of Sydney have just uncovered the genetic secret behind why this cancer almost always comes back, and it’s sparking hope—and debate—about future treatments.
On his darkest days, Mark finds comfort in Millie, his loyal 14-year-old border collie, who stays by his side. But the journey to this point has been harrowing. In January, Mark experienced a terrifying loss of spatial awareness after a medical appointment. He couldn’t even grasp his car door handle, and once inside, he repeatedly shut the door on his leg. Rushed to the hospital, an MRI revealed a massive tumor—the size of two mandarins—pushing his brain to one side. Doctors operated within hours, warning his family he might not survive. ‘Saying goodbye to my wife and two boys was the hardest thing I’ve ever done,’ Mark recalls.
Against the odds, Mark survived, but his battle is far from over. After six grueling months of radiation and chemotherapy, his treatment has ended. Now, he and his family are left in limbo, knowing the cancer will return but not when. ‘It’s like a ticking time bomb,’ he says. ‘It destroys you and your family.’
And this is the part most people miss: glioblastoma’s relentless return isn’t random. The Sydney researchers, led by Professor Lenka Munoz, discovered a small group of drug-resistant cells within the tumor—dubbed ‘persister cells’—that lie dormant during chemotherapy, only to reawaken and multiply once treatment stops. These cells are fueled by a fertility gene called PRDM9, which normally regulates chromosome changes but is hijacked by cancer cells to produce cholesterol, their survival lifeline. By switching off this gene in lab models, the team drastically reduced the number of persister cells. ‘Without cholesterol, these cells simply die,’ explains Professor Munoz.
While human trials are years away, the team is collaborating with Australian company Syntara to test potential drugs in animals. This breakthrough is particularly significant because glioblastoma treatment hasn’t advanced in decades, leaving the median survival rate stagnant at just 15 months. But here’s the controversial question: if this research leads to new treatments, will they be accessible to all, or will they become another example of healthcare inequality?
Mark, alongside former Australian of the Year Richard Scolyer (who also battled glioblastoma), is now fundraising with Tour de Cure to accelerate research. ‘I won’t be here to see a cure,’ Mark admits, ‘but I hope my story inspires others to keep pushing.’
This discovery isn’t just about science—it’s about hope, resilience, and the urgent need for progress. What do you think? Is enough being done to combat cancers like glioblastoma? Share your thoughts in the comments below.
